Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs. In the nucleus, in association with RANBP3, binds cooperatively to the NES on its target protein and to the GTPase RAN in its active GTP-bound form (Ran-GTP). Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins.
Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the cargo from the export receptor. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Involved in U3 snoRNA transport from Cajal bodies to nucleoli.
Binds to late precursor U3 snoRNA bearing a TMG cap
Found in a U snRNA export complex with PHAX/RNUXA, NCBP1/CBP80, NCBP2/CBP20, RAN, XPO1 and m7G-capped RNA (By similarity). Component of a nuclear export receptor complex composed of KPNB1, RAN, SNUPN and XPO1. Found in a trimeric export complex with SNUPN, RAN and XPO1.
Found in a nuclear export complex with RANBP3 and RAN. Found in a 60S ribosomal subunit export complex with NMD3, RAN, XPO1. Interacts with DDX3X, NMD3, NUP42, NUP88, NUP214, RANBP3 and TERT.
Interacts with NEMF (via its N-terminus). Interacts with the monomeric form of BIRC5/survivin deacetylated at 'Lys-129'. Interacts with DTNBP1 and SERTAD2; the interactions translocate DTNBP1 and SERTAD2 out of the nucleus.
Interacts with ATF2. Interacts with SLC35G1 and STIM1. Interacts with DCAF8.
Interacts with CPEB3 (PubMed:22730302). Interacts with HAX1 (PubMed:23164465). Interacts with BOK; translocates to the cytoplasm (PubMed:16302269).
Interacts with HSP90AB1 (PubMed:22022502). Interacts with LRPPRC; interacts with LRPPRC alone and also when LRPPRC is in complex with EIF4E and with EIF4E sensitivity element (4ESE)-containing mRNAs to form an EIF4E-dependent mRNA export complex (PubMed:28325843)
(Microbial infection) Interacts with HIV-1 Rev
(Microbial infection) Interacts with HTLV-1 Rex
(Microbial infection) Interacts with influenza A nucleoprotein
(Microbial infection) Interacts with Epstein-Barr virus protein BMLF1
(Microbial infection) Part of a tetrameric complex composed of CRM1, importin alpha/beta dimer and the Venezuelan equine encephalitis virus (VEEV) capsid; this complex blocks the receptor-mediated transport through the nuclear pore
(Microbial infection) Interacts with SARS-CoV virus protein ORF9b; this interaction mediates protein ORF9b export out of the nucleus
Expressed in heart, brain, placenta, lung, liver, skeletal muscle, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes. Not expressed in the kidney
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to XPO1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 13
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT05983276 | Ovarian Cancer | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | PHASE2 | RECRUITING |
| NCT05985161 | Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | PHASE2 | RECRUITING |
| NCT03095612 | Non-small Cell Lung Cancer | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | PHASE1, PHASE2 | TERMINATED |
| NCT02323880 | Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | PHASE1 | COMPLETED |
| NCT02815137 | Classical Hodgkin Lymphoma | Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma | NA | COMPLETED |
| NCT02757586 | Leukemia, Lymphocytic, Chronic, B-Cell | Treatment of Chronic Lymphocytic Leukemia | N/A | UNKNOWN |
| NCT02667873 | Solid Tumors | A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors | PHASE1 | COMPLETED |
| NCT07554482 | Extranodal NK/T-cell Lymphoma | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | PHASE2 | NOT_YET_RECRUITING |
| NCT07523737 | Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma | PHASE2 | RECRUITING |
| NCT05322330 | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma | PHASE2 | UNKNOWN |